-
公开(公告)号：US10011606B2
公开(公告)日：2018-07-03
申请号：US15615380
申请日：2017-06-06
Applicant: H. Lundbeck A/S
Inventor： Jan Kehler , Lars Kyhn Rasmussen , Morten Langgård , Mikkel Jessing
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
-
![PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS](/abs-image/US/2018/06/28/US20180179200A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180179200A1
公开(公告)日：2018-06-28
申请号：US15849798
申请日：2017-12-21
Applicant: H. Lundbeck A/S
Inventor： Jan Kehler , Lars Kyhn Rasmussen , Morten Langgard , Mikkel Jessing , Paulo Jorge Vieira Vital , Karsten Juhl , Mauro Marigo
IPC: C07D471/04 , A61P25/28 , A61P25/18 , A61P25/16 , A61P25/00
CPC classification number: C07D471/04 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/28 , C07D487/04 , C07D519/00
Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
-
公开(公告)号：US09861639B2
公开(公告)日：2018-01-09
申请号：US15415073
申请日：2017-01-25
Applicant: H. Lundbeck A/S
Inventor： John Paul Kilburn , Lars Kyhn Rasmussen , Mikkel Jessing , Eman Mohamed Eldemenky , Bin Chen , Yu Jiang
IPC: A61K31/553 , A61K31/5377 , A61K31/5375 , A61K31/445 , A61K31/4545 , A61K31/40 , A61K31/506 , A61K31/454 , A61K31/4453
CPC classification number: A61K31/553 , A61K31/40 , A61K31/445 , A61K31/4453 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/5375 , A61K31/5377 , A61K31/625 , C07D209/52 , C07D211/38 , C07D213/40 , C07D239/26 , C07D267/10 , C07D295/13 , C07D401/06 , C07D403/06 , C07D413/06
Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
-
公开(公告)号：US20170202836A1
公开(公告)日：2017-07-20
申请号：US15479972
申请日：2017-04-05
Applicant: H. Lundbeck A/S
Inventor： John Paul Kilburn , Lars Kyhn Rasmussen , Mikkel Jessing , Eman Mohamed Eldemenky , Bin Chen , Yu Jiang , Allen T. Hopper
IPC: A61K31/505
CPC classification number: A61K31/505 , C07C233/66 , C07C233/73 , C07C233/75 , C07C233/78 , C07C2601/08 , C07D211/26 , C07D213/40 , C07D213/61 , C07D231/12 , C07D233/64 , C07D237/08 , C07D239/26 , C07D241/12 , C07D309/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06
Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of epilepsy.
-
公开(公告)号：US20170008898A1
公开(公告)日：2017-01-12
申请号：US15205850
申请日：2016-07-08
Applicant: H. Lundbeck A/S
Inventor： John Paul Kilburn , Lars Kyhn Rasmussen , Mikkel Jessing , Eman Mohamed Eldemenky , Bin Chen , Yu Jiang
IPC: C07D487/04 , C07D295/13 , C07D403/06 , C07D401/06 , C07D239/26 , C07D213/38 , C07D211/38
CPC classification number: A61K31/553 , A61K31/40 , A61K31/445 , A61K31/4453 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/5375 , A61K31/5377 , A61K31/625 , C07D209/52 , C07D211/38 , C07D213/40 , C07D239/26 , C07D267/10 , C07D295/13 , C07D401/06 , C07D403/06 , C07D413/06
Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
Abstract translation: 本发明涉及抑制P2X7受体的新型环胺。
-
Patent Agency Ranking
公开(公告)号：US09533992B2
公开(公告)日：2017-01-03
申请号：US15089819
申请日：2016-04-04
Applicant: H. Lundbeck A/S
Inventor： Niels Svenstrup , Klaus Bæk Simonsen , Lars Kyhn Rasmussen , Karsten Juhl , Morten Langgård , Kate Wen , Yazhou Wang
IPC: C07D487/04 , A61K31/53
CPC classification number: C07D487/04 , A61K31/53
Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
Abstract translation: 本发明涉及PDE9酶抑制剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供制备式（I）化合物的方法。 本发明还提供了治疗患有神经变性疾病的受试者的方法，其包括给予受试者治疗有效量的式（I）化合物。 本发明还提供用于治疗患有精神障碍的受试者的方法的式（I）化合物，其包括向受试者施用治疗有效量的式（I）化合物。
-
公开(公告)号：US20160318939A1
公开(公告)日：2016-11-03
申请号：US15142116
申请日：2016-04-29
Applicant: H. Lundbeck A/S
Inventor： Jan Kehler , Lars Kyhn Rasmussen , Morten Langgård , Mikkel Jessing , Paulo Jorge Vieira Vital , Karsten Juhl
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Abstract translation: 本发明提供作为PDE1抑制剂的咪唑并吡嗪酮及其作为药物的用途，特别是用于治疗神经变性疾病和精神障碍。
-
公开(公告)号：US20160311831A1
公开(公告)日：2016-10-27
申请号：US15133715
申请日：2016-04-20
Applicant: H. Lundbeck A/S
Inventor： Jan Kehler , Lars Kyhn Rasmussen , Morten Langgård , Mikkel Jessing , Paulo Jorge Vieira Vital , Karsten Juhl
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The present invention provides imidazotriazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Abstract translation: 本发明提供作为PDE1抑制剂的咪唑并三氮嗪酮及其作为药物的用途，特别是用于治疗神经变性疾病和精神障碍。
-
公开(公告)号：US09415055B2
公开(公告)日：2016-08-16
申请号：US14793773
申请日：2015-07-08
Applicant: H. Lundbeck A/S
Inventor： John Paul Kilburn , Lars Kyhn Rasmussen , Mikkel Jessing , Eman Mohamed Eldemenky , Bin Chen , Yu Jiang
IPC: A61K31/40 , A61K31/445 , A61K31/4453 , A61K31/506 , A61K31/4545 , A61K31/5375 , A61K31/5377 , A61K31/553 , A61K31/625 , C07D211/38 , C07D213/40 , C07D239/26 , C07D267/10 , C07D295/13 , C07D401/06 , C07D403/06 , C07D413/06 , C07D209/52
CPC classification number: A61K31/553 , A61K31/40 , A61K31/445 , A61K31/4453 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/5375 , A61K31/5377 , A61K31/625 , C07D209/52 , C07D211/38 , C07D213/40 , C07D239/26 , C07D267/10 , C07D295/13 , C07D401/06 , C07D403/06 , C07D413/06
Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
-
公开(公告)号：US20160213674A1
公开(公告)日：2016-07-28
申请号：US15089819
申请日：2016-04-04
Applicant: H. Lundbeck A/S
Inventor： Niels Svenstrup , Klaus Bæk Simonsen , Lars Kyhn Rasmussen , Karsten Juhl , Morten Langgård , Kate Wen , Yazhou Wang
IPC: A61K31/53
CPC classification number: C07D487/04 , A61K31/53
Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
Abstract translation: 本发明涉及PDE9酶抑制剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供制备式（I）化合物的方法。 本发明还提供了治疗患有神经变性疾病的受试者的方法，其包括给予受试者治疗有效量的式（I）化合物。 本发明还提供用于治疗患有精神障碍的受试者的方法的式（I）化合物，其包括向受试者施用治疗有效量的式（I）化合物。
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.041 seconds)
